Bristol-Myers Squibb to Present at the Morgan Stanley Global Healthcare Unplugged Conference

NEW YORK--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) will present at the 2010 Morgan Stanley Global Healthcare Unplugged Conference on Monday, September 13, 2010, in New York. Elliott Sigal, executive vice president, chief scientific officer and president, Research & Development, will make a presentation about the company at 8:35 a.m. EDT.

Investors and the general public are invited to listen to a live webcast of the presentation at http://investor.bms.com. An archived edition of the presentation will be available later that day.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit www.bms.com or follow us on Twitter at http://twitter.com/bmsnews.



CONTACT:

Bristol-Myers Squibb Company
Media:
Jennifer Fron Mauer, 609-252-6579
[email protected]
or
Investors:
John Elicker, 609-252-4611
[email protected]

KEYWORDS:   United States  North America  New York

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical  Professional Services  Banking  Finance  Communications  Public Relations/Investor Relations  General Health

MEDIA:

Logo
 Logo

Suggested Articles

Gilead Sciences is paying Nurix $45 million upfront in a deal that could reach $2.3 billion in value if all milestones are met and royalties realized.

In mice, Kymera's lead drug promoted tumor regression, both on its own and in combination with BTK inhibitor Imbruvica.

The report features testimony that some NHS bodies are “actively instructed not to deal with industry by their local leadership.”